Noradrenergic and serotoninergic depression?

Yazıcı, Olcay; Arıcıoğlu, Feyza; Gürvit, Gülay; Üçok, Alp; Taştaban, Yildiz; Canberk, Özge; Özgüroğlu, Mustafa; Durat, Tayfun; Doğan, Şahin

doi:10.1016/0165-0327(93)90085-x

Cited by 8 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, Ko et al found that responders to fluoxetine exhibit higher pretreatment pMHPG levels than those of non-responders among patients with unipolar depression [18]. Yazici et al reported an obvious decrease in MHPG excretion during treatment with clomipramine or maprotiline in depressed patients with high pretreatment levels of MHPG [47]. Coplan et al reported that a greater degree of clinical improvement with fluoxetine treatment is predicted by a greater magnitude of basal pMHPG reduction in patients with panic disorder [8].…”

Section: Discussionmentioning

confidence: 98%

Plasma Levels of Catecholamine Metabolites Predict the Response to Sulpiride or Fluvoxamine in Major Depression

Ueda¹,

Yoshimura²,

Shinkai³

et al. 2002

Pharmacopsychiatry

View full text Add to dashboard Cite

We investigated the relationships between the changes in plasma catecholamine metabolites obtained from depressed patients before and after administration of sulpiride, a benzamide compound, or fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), and between clinical responses to treatment with each of these drugs. Responders to sulpiride had significantly lower plasma homovanillic acid (pHVA) levels before administration of sulpiride than did non-responders or controls (responders: 4.5 +/- 3.1 ng/ml, non-responders: 11.1 +/- 5.9 ng/ml, controls: 10.9 +/- 5.3 ng/ml). Positive relationships were observed between changes in pHVA levels and improvement rates in the 17-item Hamilton Depression Rating Scale (Ham-D). In contrast, responders to fluvoxamine had significantly higher plasma free 3-methoxy-4-hydroxyphenylglycol (pMHPG) levels before administration of fluvoxamine than did non-responders or controls (responders: 8.5 +/- 1.8 ng/ml, non-responders: 5.9 +/- 2.I ng/ml, controls: 5.2 +/- 2.9 ng/ml). Negative relationships were observed between changes in pMHPG levels and improvement rates in Ham-D. These results suggest that lower pretreatment pHVA levels and higher pretreatment levels of pMHPG might be predictors of response to sulpiride and fluvoxamine, respectively, and that sulpiride might produce a functional increase in the dopaminergic system, resulting in improvement in some depressive symptoms; fluvoxamine, on the other hand, might produce a functional decrease in the noradrenergic system via serotonergic neurons, resulting in improvement of those symptoms.

show abstract

Section: Discussionmentioning

confidence: 98%

Plasma Levels of Catecholamine Metabolites Predict the Response to Sulpiride or Fluvoxamine in Major Depression

Ueda¹,

Yoshimura²,

Shinkai³

et al. 2002

Pharmacopsychiatry

View full text Add to dashboard Cite

show abstract

“…Indeed, it has been in this area that much of the development of medications has focused in recent years, yielding clinically effective antidepressants believed to act largely by enhancing serotonergic activity (known as selective serotonin reuptake inhibitors, SSRIs; Grimsley and Jann 1992;Rickels and Schweizer 1990). In contrast, the role that NE plays in psychiatric function has been heavily debated (Grimsley and Jann 1992;Maas and Huang 1980;Montgomery 1997;Rickels and Schweizer 1990;Waldmeier 1981;Yazici et al 1993), although NE reuptake inhibitors (NRIs) have also been developed for the treatment of depression (Chouinard et al 1984;Wong et al 2000). Additionally, a number of drugs (known as "dual action antidepressants") that act on the uptake of both 5-HT and NE have been developed (Pacher and Kecskemeti 2004).…”

Section: Introductionmentioning

confidence: 91%

Neurochemical responses to antidepressants in the prefrontal cortex of mice and their efficacy in preclinical models of anxiety-like and depression-like behavior: a comparative and correlational study

Kobayashi

Hayashi²,

Shimamura³

et al. 2008

Psychopharmacology

View full text Add to dashboard Cite

show abstract

An evaluation of the role of the noradrenergic system in the neurobiology of depression: a review

Redmond

Leonard

1997

Hum. Psychopharmacol. Clin. Exp.

View full text Add to dashboard Cite

With increased understanding of the neurobiology of depression, the role of the noradrenergic system is achieving greater significance. Unfortunately, the exact role of noradrenaline in depressive disorders is difficult to determine due to contradictory and inconsistent results from metabolite (MHPG) and receptor (α‐ and β‐adrenoceptors) binding studies which appear to be due to differences in experimental methods and variations between the age of tissue samples and the patient groups being studied. The role of tyrosine hydroxylase, the rate‐limiting enzyme in the synthesis of noradrenaline has only recently been explored. A downregulation of tyrosine hydroxylase mRNA expression seems to be a common mechanism of action of antidepressant treatments and indicates that the site of action of antidepressants may occur at the level of gene expression. Evidence suggests that corticotrophin releasing factor (CRF) may regulate tyrosine hydroxylase activity and so may provide a link between the monoamine and endocrine theories of depression. Glutamate and sigma receptors have also been implicated in having a role to play in affective disorders and will be discussed in this review as these receptors may be indirectly involved in modulating the activity of the noradrenergic system. © 1997 John Wiley & Sons, Ltd.

show abstract

Noradrenergic and serotoninergic depression?

Cited by 8 publications

References 17 publications

Plasma Levels of Catecholamine Metabolites Predict the Response to Sulpiride or Fluvoxamine in Major Depression

Plasma Levels of Catecholamine Metabolites Predict the Response to Sulpiride or Fluvoxamine in Major Depression

Neurochemical responses to antidepressants in the prefrontal cortex of mice and their efficacy in preclinical models of anxiety-like and depression-like behavior: a comparative and correlational study

An evaluation of the role of the noradrenergic system in the neurobiology of depression: a review

Contact Info

Product

Resources

About